Phase II trial of cisplatin plus prednisone in docetaxel-refractory castration-resistant prostate cancer patients

Carlo Buonerba, Piera Federico, Carmine D'Aniello, Pasquale Rescigno, Carla Cavaliere, Livio Puglia, Matteo Ferro, Vincenzo Altieri, Sisto Perdonà, Sabino De Placido, Giuseppe Di Lorenzo

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Background: Docetaxel represents the first-line treatment for castration-resistant prostate cancer (CRPC). New therapeutic options are needed for subsequent lines of therapy in CRPC patients. Methods: Patients with progressive CRPC, pretreated with docetaxel, were enrolled at the Department of Molecular and Clinical Oncology and Endocrinology of University 'Federico II of Naples' from April 2007 to January 2010. Accrued patients received cisplatin at the dose of 75 mg/m2 every 3 weeks with daily 10 mg prednisone. Measures of response and progression were defined according to the Prostate Cancer Working Group (PCWG1) criteria. Toxicity was graded according to the Common Toxicity Criteria of the National Cancer Institute, version 3.0. Results: Twenty-five patients were recruited. Median age was 65 years (interquartile range 55-74 years). All patients were evaluable for PSA response and toxicity and thirteen patients (52%) were evaluable for measurable disease. A total of 170 cycles of cisplatin chemotherapy were administered. Median dose intensity corresponded to 96% (range 83.8-98.3%) of the maximum dose intensity that could be delivered. Three patients (12%) presented grade 3-4 neuropathy and ten (40%) presented grade 3-4 neutropenia. Five patients (20%) showed a greater than 50% PSA decline, and three of thirteen patients with measurable disease presented a partial response. Median progression-free survival was 5.6 months (24 weeks; range 15-24). Median survival was 55 weeks (range 46-64; see Fig. 1). Conclusions: Cisplatin plus prednisone appears to represent an active regimen in docetaxel-refractory CRPC with an acceptable toxicity profile. Further investigations in this setting are warranted to confirm these early encouraging findings.

Original languageEnglish
Pages (from-to)1455-1461
Number of pages7
JournalCancer Chemotherapy and Pharmacology
Volume67
Issue number6
DOIs
Publication statusPublished - Jun 2011

Fingerprint

docetaxel
Castration
Prednisone
Refractory materials
Cisplatin
Toxicity
Prostatic Neoplasms
Endocrinology
Oncology
Chemotherapy
Medical Oncology
National Cancer Institute (U.S.)
Neutropenia

Keywords

  • Castration-resistant prostate cancer
  • Cisplatin
  • Pretreated patients

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Pharmacology
  • Pharmacology (medical)
  • Toxicology

Cite this

Buonerba, C., Federico, P., D'Aniello, C., Rescigno, P., Cavaliere, C., Puglia, L., ... Lorenzo, G. D. (2011). Phase II trial of cisplatin plus prednisone in docetaxel-refractory castration-resistant prostate cancer patients. Cancer Chemotherapy and Pharmacology, 67(6), 1455-1461. https://doi.org/10.1007/s00280-011-1594-z

Phase II trial of cisplatin plus prednisone in docetaxel-refractory castration-resistant prostate cancer patients. / Buonerba, Carlo; Federico, Piera; D'Aniello, Carmine; Rescigno, Pasquale; Cavaliere, Carla; Puglia, Livio; Ferro, Matteo; Altieri, Vincenzo; Perdonà, Sisto; De Placido, Sabino; Lorenzo, Giuseppe Di.

In: Cancer Chemotherapy and Pharmacology, Vol. 67, No. 6, 06.2011, p. 1455-1461.

Research output: Contribution to journalArticle

Buonerba, C, Federico, P, D'Aniello, C, Rescigno, P, Cavaliere, C, Puglia, L, Ferro, M, Altieri, V, Perdonà, S, De Placido, S & Lorenzo, GD 2011, 'Phase II trial of cisplatin plus prednisone in docetaxel-refractory castration-resistant prostate cancer patients', Cancer Chemotherapy and Pharmacology, vol. 67, no. 6, pp. 1455-1461. https://doi.org/10.1007/s00280-011-1594-z
Buonerba, Carlo ; Federico, Piera ; D'Aniello, Carmine ; Rescigno, Pasquale ; Cavaliere, Carla ; Puglia, Livio ; Ferro, Matteo ; Altieri, Vincenzo ; Perdonà, Sisto ; De Placido, Sabino ; Lorenzo, Giuseppe Di. / Phase II trial of cisplatin plus prednisone in docetaxel-refractory castration-resistant prostate cancer patients. In: Cancer Chemotherapy and Pharmacology. 2011 ; Vol. 67, No. 6. pp. 1455-1461.
@article{326a8ed4853343c686a5d502886c933b,
title = "Phase II trial of cisplatin plus prednisone in docetaxel-refractory castration-resistant prostate cancer patients",
abstract = "Background: Docetaxel represents the first-line treatment for castration-resistant prostate cancer (CRPC). New therapeutic options are needed for subsequent lines of therapy in CRPC patients. Methods: Patients with progressive CRPC, pretreated with docetaxel, were enrolled at the Department of Molecular and Clinical Oncology and Endocrinology of University 'Federico II of Naples' from April 2007 to January 2010. Accrued patients received cisplatin at the dose of 75 mg/m2 every 3 weeks with daily 10 mg prednisone. Measures of response and progression were defined according to the Prostate Cancer Working Group (PCWG1) criteria. Toxicity was graded according to the Common Toxicity Criteria of the National Cancer Institute, version 3.0. Results: Twenty-five patients were recruited. Median age was 65 years (interquartile range 55-74 years). All patients were evaluable for PSA response and toxicity and thirteen patients (52{\%}) were evaluable for measurable disease. A total of 170 cycles of cisplatin chemotherapy were administered. Median dose intensity corresponded to 96{\%} (range 83.8-98.3{\%}) of the maximum dose intensity that could be delivered. Three patients (12{\%}) presented grade 3-4 neuropathy and ten (40{\%}) presented grade 3-4 neutropenia. Five patients (20{\%}) showed a greater than 50{\%} PSA decline, and three of thirteen patients with measurable disease presented a partial response. Median progression-free survival was 5.6 months (24 weeks; range 15-24). Median survival was 55 weeks (range 46-64; see Fig. 1). Conclusions: Cisplatin plus prednisone appears to represent an active regimen in docetaxel-refractory CRPC with an acceptable toxicity profile. Further investigations in this setting are warranted to confirm these early encouraging findings.",
keywords = "Castration-resistant prostate cancer, Cisplatin, Pretreated patients",
author = "Carlo Buonerba and Piera Federico and Carmine D'Aniello and Pasquale Rescigno and Carla Cavaliere and Livio Puglia and Matteo Ferro and Vincenzo Altieri and Sisto Perdon{\`a} and {De Placido}, Sabino and Lorenzo, {Giuseppe Di}",
year = "2011",
month = "6",
doi = "10.1007/s00280-011-1594-z",
language = "English",
volume = "67",
pages = "1455--1461",
journal = "Cancer Chemotherapy and Pharmacology",
issn = "0344-5704",
publisher = "Springer Verlag",
number = "6",

}

TY - JOUR

T1 - Phase II trial of cisplatin plus prednisone in docetaxel-refractory castration-resistant prostate cancer patients

AU - Buonerba, Carlo

AU - Federico, Piera

AU - D'Aniello, Carmine

AU - Rescigno, Pasquale

AU - Cavaliere, Carla

AU - Puglia, Livio

AU - Ferro, Matteo

AU - Altieri, Vincenzo

AU - Perdonà, Sisto

AU - De Placido, Sabino

AU - Lorenzo, Giuseppe Di

PY - 2011/6

Y1 - 2011/6

N2 - Background: Docetaxel represents the first-line treatment for castration-resistant prostate cancer (CRPC). New therapeutic options are needed for subsequent lines of therapy in CRPC patients. Methods: Patients with progressive CRPC, pretreated with docetaxel, were enrolled at the Department of Molecular and Clinical Oncology and Endocrinology of University 'Federico II of Naples' from April 2007 to January 2010. Accrued patients received cisplatin at the dose of 75 mg/m2 every 3 weeks with daily 10 mg prednisone. Measures of response and progression were defined according to the Prostate Cancer Working Group (PCWG1) criteria. Toxicity was graded according to the Common Toxicity Criteria of the National Cancer Institute, version 3.0. Results: Twenty-five patients were recruited. Median age was 65 years (interquartile range 55-74 years). All patients were evaluable for PSA response and toxicity and thirteen patients (52%) were evaluable for measurable disease. A total of 170 cycles of cisplatin chemotherapy were administered. Median dose intensity corresponded to 96% (range 83.8-98.3%) of the maximum dose intensity that could be delivered. Three patients (12%) presented grade 3-4 neuropathy and ten (40%) presented grade 3-4 neutropenia. Five patients (20%) showed a greater than 50% PSA decline, and three of thirteen patients with measurable disease presented a partial response. Median progression-free survival was 5.6 months (24 weeks; range 15-24). Median survival was 55 weeks (range 46-64; see Fig. 1). Conclusions: Cisplatin plus prednisone appears to represent an active regimen in docetaxel-refractory CRPC with an acceptable toxicity profile. Further investigations in this setting are warranted to confirm these early encouraging findings.

AB - Background: Docetaxel represents the first-line treatment for castration-resistant prostate cancer (CRPC). New therapeutic options are needed for subsequent lines of therapy in CRPC patients. Methods: Patients with progressive CRPC, pretreated with docetaxel, were enrolled at the Department of Molecular and Clinical Oncology and Endocrinology of University 'Federico II of Naples' from April 2007 to January 2010. Accrued patients received cisplatin at the dose of 75 mg/m2 every 3 weeks with daily 10 mg prednisone. Measures of response and progression were defined according to the Prostate Cancer Working Group (PCWG1) criteria. Toxicity was graded according to the Common Toxicity Criteria of the National Cancer Institute, version 3.0. Results: Twenty-five patients were recruited. Median age was 65 years (interquartile range 55-74 years). All patients were evaluable for PSA response and toxicity and thirteen patients (52%) were evaluable for measurable disease. A total of 170 cycles of cisplatin chemotherapy were administered. Median dose intensity corresponded to 96% (range 83.8-98.3%) of the maximum dose intensity that could be delivered. Three patients (12%) presented grade 3-4 neuropathy and ten (40%) presented grade 3-4 neutropenia. Five patients (20%) showed a greater than 50% PSA decline, and three of thirteen patients with measurable disease presented a partial response. Median progression-free survival was 5.6 months (24 weeks; range 15-24). Median survival was 55 weeks (range 46-64; see Fig. 1). Conclusions: Cisplatin plus prednisone appears to represent an active regimen in docetaxel-refractory CRPC with an acceptable toxicity profile. Further investigations in this setting are warranted to confirm these early encouraging findings.

KW - Castration-resistant prostate cancer

KW - Cisplatin

KW - Pretreated patients

UR - http://www.scopus.com/inward/record.url?scp=79959583223&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79959583223&partnerID=8YFLogxK

U2 - 10.1007/s00280-011-1594-z

DO - 10.1007/s00280-011-1594-z

M3 - Article

VL - 67

SP - 1455

EP - 1461

JO - Cancer Chemotherapy and Pharmacology

JF - Cancer Chemotherapy and Pharmacology

SN - 0344-5704

IS - 6

ER -